2006–2010
Early in-clinic trials
Start of Artificial Pancreas project at Cambridge with trials in children with type 1 diabetes. Joined the JDRF Artificial Pancreas Consortium. Cambridge algorithm stress-tested following exercise and alcohol consumption in adults with type 1 diabetes. Cambridge algorithm evaluated in pregnant women with type 1 diabetes.
2011–2014
Night-only and free-living feasibility trials
Overnight use of Cambridge algorithm evaluated by children, adults and pregnant women with type 1 diabetes. Cambridge algorithm used day-and-night over seven days by adults with type 1 diabetes.
2015–2016
Short day-and-night free-living trials
Cambridge algorithm used by well-controlled adults with type 1 diabetes over four weeks. Cambridge algorithm used by adolescents with type 1 diabetes over three weeks.
2017–2018
Longer day-and-night and young-children trials
Cambridge algorithm used over three months by children and adults with type 1 diabetes. Cambridge algorithm used over two years by children and adolescents from onset of diabetes. Cambridge algorithm used in young children one to seven years old with type 1 diabetes.
2019
Transition to CamAPS FX
CamAPS FX app used by older adults with type 1 diabetes. CamAPS FX app used throughout pregnancy by pregnant women with type 1 diabetes. CamAPS FX app used in children aged one to seven years old with type 1 diabetes.
2020 onwards
Regulatory approval, commercialisation, clinical trialling
CamAPS FX app CE-marked for use in the EU and the UK. Research continues to assess benefits and support reimbursement.